Meeting
2019 Genitourinary Cancers Symposium
Phase II study of sitravatinib in combination with nivolumab in patients undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (ccRCC).
Authors
Jose A. Karam
The University of Texas MD Anderson Cancer Center, Houston, TX
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03680521
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS686)
DOI
10.1200/JCO.2019.37.7_suppl.TPS686
Abstract #
TPS686
Poster Bd #
K17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Effect of sitravatinib combined with PD-1 blockade on cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.
First Author: Ashten Omstead
Poster
2021 Genitourinary Cancers Symposium
Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.
First Author: Pavlos Msaouel
Poster
2018 ASCO Annual Meeting
Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
First Author: Shubham Pant
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
First Author: Anwaar Saeed